Protyon offers an analysis service that will examine the impact of mutations in specific proteins targeted for treatment in lung cancer and use this analysis to suggest therapy options.

We will create a computational model of the mutated protein which will be analysed by experts to assess which targeted therapies may be impacted by these mutations and those that may be unaffected by the mutation. Current analysis is available for EGFR and BRAF, with additional drivers being added in the future. A written report can be supplemented with a personal explanation if required.